Total
0
Shares
TBG Diagnostics (ASX:TDL) to sell COVID-19 test kits after Chinese Govt. law lifted
  • TBG Diagnostics (TDL) has reported that its investee company, TBG Biotechnology Xiamen, can now sell its COVID-19 test kits to Europe
  • Last month, the Chinese Government introduced new measures to stop the sale of faulty or fake COVID-19 test kits, meaning all devices needed to have a Chinese medical device product registration certificate
  • However, now the Government has lifted the ban, giving TBG the green light to sell its COVID-19 test kits in Europe
  • TBG Diagnostics is in a trading halt after a sudden spike in its share price which it claims was due to its investee company receiving CE mark approval for the test kits. Company shares last traded for 27 cents each on March 17

TBG Diagnostics (TDL) has reported that its investee company, TBG Biotechnology Xiamen, can now sell its COVID-19 test kits to Europe.

TBG has a 46.55 per cent holding in TBG Xiamen, which is a China-based molecular diagnostics company.

Last month, the company was unable to sell its test kits due to new government laws.

The Chinese Government banned the export of all COVID-19 diagnostic kits that have not obtained the required China medical device product registration certificate. This rule was to stop the sale of faulty or fake COVID-19 kits.

However, now the Chinese Government has lifted the ban, this has given TBG the green light to sell its COVID-19 test kits outside the country.

"Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit," the company said.

In March, TBG received a European CE Mark approval for its diagnostic kits.

TBG Diagnostics is in a trading halt after a sudden spike in its share price, which it claims was due to the investee company receiving CE mark approval for the test kits. Company shares last traded for 27 cents each on March 17.


Subscribe


TDL by the numbers
More From The Market Herald
Opthea (ASX:OPT) - CEO & Managing Director, Dr Megan Baldwin - The Market Herald

" Opthea (ASX:OPT) raises A$180.3M following NASDAQ IPO

Opthea (OPT) has completed its initial public offering to list on the United States’ NASDAQ stock exchange.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) granted European patent for IMP761

Immutep (IMM) has been granted a European patent for IMP761, an anti-LAG-3 antibody.
Anatara Lifesciences (ASX:ANR) - Chair, Sue MacLeman - The Market Herald

" Anatara Lifesciences (ASX:ANR) to undertake $1.67M placement

Anatara Lifesciences (ANR) has received firm commitments to undertake a $1.67 million placement.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) hit with ASIC restrictions

Shares in Holista CollTech (HCT) have nosedived today after the Australian Securities and Investments Commission (ASIC) punished the company for continuous disclosure breaches.